Mizuho Securities Reiterates a Buy Rating on Amgen Inc (AMGN)

By Carrie Williams

Mizuho Securities analyst Salim Syed reiterated a Buy rating on Amgen Inc (AMGNResearch Report) on June 21 and set a price target of $208. The company’s shares closed on Friday at $187.11.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.0% and a 47.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Neon Therapeutics Inc.

Amgen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $208.92.

See today’s analyst top recommended stocks >>

The company has a one-year high of $210.19 and a one-year low of $166.30. Currently, Amgen Inc has an average volume of 2.85M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.